US FDA’s Patent ‘Concerns’ Include Thickets, Product Hopping, And Evergreening

 
• By Nielsen Hobbs

Senators press for sharing of FDA applications with PTO as Woodcock letter seeks collaboration on everything from PTAB to patent term extensions to ‘possible misuse of the patent system.’

With a report due to Congress in January, Orange Book patent issues may find their way into user fee reauthorization legislation next year. • Source: Nielsen Hobbs

The US Food and Drug Administration is seeking to work with the Patent and Trademark Office on a variety of hot-button issues, but it seems unclear how much impact the collaboration will have on the intellectual property landscape for the pharmaceutical industry.

Nevertheless, the 10 September

More from Legal & IP

More from Pink Sheet